Clinical Trial Update: Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating azacitidine plus arsenic trioxide in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia; the study was termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED